Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine.
Afferi L, Spahn M, Hayoz S, Strebel RT, Rothschild SI, Seifert H, Özdemir BC, Kiss B, Maletzki P, Engeler D, Wirth G, Hadaschik B, Lucca I, John H, Sauer A, Müntener M, Bubendorf L, Schneider M, Musilova J, Petrausch U, Cathomas R; Swiss Group for Clinical Cancer Research (SAKK). Afferi L, et al. Among authors: ozdemir bc. BJU Int. 2024 Mar 8. doi: 10.1111/bju.16318. Online ahead of print. BJU Int. 2024. PMID: 38456541
Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort.
Richters A, Robbrecht DGJ, Meijer RP, van der Heijden AG, Kiemeney LALM, van den Bosch J, Suelmann BBM, Özdemir BC; ProBCI Study Group; Mehra N, Aben KKH. Richters A, et al. Among authors: ozdemir bc. Eur Urol Open Sci. 2023 Dec 20;59:50-54. doi: 10.1016/j.euros.2023.11.010. eCollection 2024 Jan. Eur Urol Open Sci. 2023. PMID: 38213646 Free PMC article.
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Cathomas R, Rothschild SI, Hayoz S, Bubendorf L, Özdemir BC, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel RT, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U. Cathomas R, et al. Among authors: ozdemir bc. J Clin Oncol. 2023 Nov 20;41(33):5131-5139. doi: 10.1200/JCO.23.00363. Epub 2023 Aug 17. J Clin Oncol. 2023. PMID: 37590894 Clinical Trial.
Correction to: Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune‑related adverse events among cancer patients.
Özdemir BC, Espinosa da Silva C, Arangalage D, Monney P, Guler SA, Huynh-Do U, Stirnimann G, Possamai L, Trepp R, Hoepner R, Salmen A, Gerard CL, Hruz P, Christ L, Rothschild SI. Özdemir BC, et al. Cancer Immunol Immunother. 2023 Jul;72(7):2003-2004. doi: 10.1007/s00262-023-03456-w. Cancer Immunol Immunother. 2023. PMID: 37154850 Free PMC article. No abstract available.
43 results